SureTrader
Interactive Brokers Advertisement
Home > Boards > US Listed > Biotechs > Advaxis, Inc. (ADXS)

ADXS got similar—but slightly better—financial terms in the

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (3) | Next 10 | Previous | Next
DewDiligence Member Profile
Member Level 
Followed By 662
Posts 100,925
Boards Moderated 25
Alias Born 09/05/02
160x600 placeholder
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 10/12/2017 3:55:36 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 10/2/2017 4:31:51 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 10/2/2017 4:31:51 PM
Amended Statement of Ownership (sc 13g/a) "Edgar (US Regulatory)" - 9/27/2017 8:51:46 AM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 9/26/2017 5:26:54 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 9/25/2017 4:55:48 PM
Biotech's Recently Under the Microscope, Analyst Coverage "InvestorsHub NewsWire" - 9/20/2017 8:00:00 AM
Advaxis to Present at Cantor Fitzgerald Global Healthcare Conference "Business Wire" - 9/18/2017 9:02:00 AM
Quarterly Report (10-q) "Edgar (US Regulatory)" - 9/11/2017 4:34:01 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 9/11/2017 4:07:05 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 9/5/2017 4:31:58 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 9/5/2017 4:31:58 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 8/1/2017 4:33:09 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 8/1/2017 4:32:40 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 7/21/2017 5:02:24 PM
Initial Statement of Beneficial Ownership (3) "Edgar (US Regulatory)" - 7/12/2017 5:31:49 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 7/7/2017 6:04:08 AM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 7/3/2017 4:33:21 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 7/3/2017 4:32:55 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 7/3/2017 4:32:24 PM
Advaxis’ Axalimogene Filolisbac Data Selected for Poster Presentation at ESGO 2017 "Business Wire" - 6/26/2017 8:55:00 AM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 6/20/2017 6:32:13 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 6/20/2017 6:31:48 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 6/20/2017 6:31:48 PM
Advaxis to Present at 2017 BIO International Convention "Business Wire" - 6/16/2017 8:00:00 AM
DewDiligence Member Level  Tuesday, 10/03/17 08:10:43 PM
Re: fbg0316 post# 37079
Post # of 38784 
ADXS got similar—but slightly better—financial terms in the NEO deal than CTMX got in the bi-specific-mAb collaboration with AMGN announced today:

http://ir.cytomx.com/phoenix.zhtml?c=254195&p=irol-newsArticle&ID=2304423
Quote:
Under the terms of the agreement, Amgen and CytomX will co-develop a Probody T-cell engaging bispecific against EGFRxCD3 with CytomX leading early development. Amgen will lead later development and commercialization with global late-stage development costs shared between the two companies.

Amgen will make an upfront payment of $40 million and purchase $20 million of CytomX common stock. CytomX will be eligible to receive up to $455 million in development, regulatory and commercial milestones for the EGFR program.

It’s curious how similar the financial terms of the two deals are.


“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”
Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (3) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist